openPR Logo
Press release

Biosimilar Market Analysis, Share and Size, Trends, Industry Growth And Segment Forecasts To 2022

03-19-2018 02:14 PM CET | Health & Medicine

Press release from: (MRE) Report

Biosimilar Market Share

Biosimilar Market Share

New York, March 18, 2018: The Biosimilar Market is expected to exceed more than US$ 13.86 Billion by 2022 at a CAGR of 26.0% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Samsung Bioepis (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion, Inc. (South Korea), and Biocon Ltd. (India). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The scope of the report includes a detailed study of global and regional markets onBiosimilar Market with the reasons given for variations in the growth of the industry in certain regions.

You Can Find Full Report: https://www.marketresearchengine.com/biosimilar-market-report

The Biosimilar Market has been segmented as below: (Accordingly)

By Manufacturing Type Analysis:
• In-house Manufacturing
• Contract Manufacturing Organizations

By Application Analysis:
• Oncology
• Blood Disorders
• Chronic & Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Applications

By Product Analysis
• Recombinant Non-Glycosylated Proteins
o Insulin
o Recombinant Human Growth Hormones
o Granulocyte Colony-stimulating Factor
o Interferons
• Recombinant Glycosylated Proteins
o Erythropoietin
o Monoclonal Antibodies
o Follitropin
• Recombinant Peptides
o Glucagon
o Calcitonin

By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World

Request Sample Report here @: https://www.marketresearchengine.com/biosimilar-market-report

This report provides:

1) An overview of the global market for Biosimilar Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
3) Identifications of new market opportunities and targeted promotional plans for Biosimilar Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.

The major driving factors of Biosimilar Market are as follows:
• Expanding Government Support and Initiatives to Develop and Promote Biosimilars
• Developing Pressure to Curtail Healthcare Expenditure
• Growth in population of senior citizens
• Increasing Pressure to reduce or cut Healthcare Expenditure
• Increase in clinical trial activities and awareness
• Low cost of biosimilar drugs increases the demand for use

The restraining factors of Biosimilar Market are as follows:
• Complexities in assembling and creative procedures by biologic medication producers.

The Biosimilar Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

About Us

Market Research Engine (MRE) is a next-generation provider of syndicated research, customized research, and consulting services. MRE’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each Market Research Engine’s research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Media Contact

Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Country: United States
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Market Analysis, Share and Size, Trends, Industry Growth And Segment Forecasts To 2022 here

News-ID: 983862 • Views:

More Releases from (MRE) Report

Weight Management Market is Expected To Be Worth US$ 442 Billion By 2025
Weight Management Market is Expected To Be Worth US$ 442 Billion By 2025
New York, March 26, 2018: Weight Management Market 2018 The Global Weight Management Market is expected to exceed more than US$ 442.0 Billion by 2025 at a CAGR of 8.0% in the given forecast period. The scope of the report includes a detailed study of global and regional markets on Global Weight Management Market with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed
Home Healthcare Market is Expected To Be Worth US$ 300 Billion By 2022
Home Healthcare Market is Expected To Be Worth US$ 300 Billion By 2022
New York, March 26, 2018: Home Healthcare Market 2018 The Global Home Healthcare Market is expected to exceed more than US$ 300.7 Billion by 2022 at a CAGR of 7.4% in the given forecast period. The scope of the report includes a detailed study of global and regional markets on Global Home Healthcare Market with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed
Healthcare 3D Printing Market is Forecast to Cross US$ 4 Billion By 2022
Healthcare 3D Printing Market is Forecast to Cross US$ 4 Billion By 2022
New York, March 26, 2018: Healthcare 3D Printing Market 2018 The Global Healthcare 3D Printing Market is expected to exceed more than US$ 4 Billion by 2022 at a CAGR of 21.0% in the given forecast period. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include 3D Systems, Arcam AB, Renishaw PLC., EoS
Tumor Ablation Market is Projected to Reach US$ 650 Million By 2022
Tumor Ablation Market is Projected to Reach US$ 650 Million By 2022
New York, March 26, 2018: Tumor Ablation Market 2018 The Global Tumor Ablation Market is expected to exceed more than US$ 650 Million by 2022 at a CAGR of 12.0% in the given forecast period. The scope of the report includes a detailed study of global and regional markets for Global Tumor Ablation Market with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.